Datapoint: Entresto Scores Expanded Heart Failure Label

The FDA last week approved a label expansion for Novartis’s Entresto, boosting its potential patient pool by millions of lives. The blockbuster drug is now approved for both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in patients whose left ventricular ejection fraction (LVEF) is below normal levels. For the treatment of chronic heart failure, Entresto currently holds preferred formulary placement for 50% of all covered lives, growing to 78% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/17/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today